NovoCure to Acquire Integra LifeSciences for $1B
Ticker: IART · Form: 8-K · Filed: May 13, 2025 · CIK: 917520
| Field | Detail |
|---|---|
| Company | Integra Lifesciences Holdings Corp (IART) |
| Form Type | 8-K |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, healthcare
TL;DR
Integra LifeSciences is being bought by NovoCure for $1B, deal expected to close Q3 2025.
AI Summary
Integra LifeSciences Holdings Corp. announced on May 9, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of NovoCure Limited. The transaction is valued at approximately $1.0 billion. The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could significantly impact the medical device and oncology sectors, potentially leading to new treatment options and market consolidation.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.
Key Numbers
- $1.0B — Acquisition Value (Total consideration for Integra LifeSciences)
- Q3 2025 — Expected Closing (Anticipated timeframe for the transaction to be finalized)
Key Players & Entities
- Integra LifeSciences Holdings Corp. (company) — Company being acquired
- NovoCure Limited (company) — Acquiring company
- $1.0 billion (dollar_amount) — Acquisition valuation
- May 9, 2025 (date) — Date of definitive agreement
- third quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement between Integra LifeSciences and NovoCure?
The definitive agreement values Integra LifeSciences at approximately $1.0 billion.
Who is acquiring Integra LifeSciences Holdings Corp.?
Integra LifeSciences Holdings Corp. is being acquired by an affiliate of NovoCure Limited.
When is the acquisition expected to be completed?
The acquisition is expected to close in the third quarter of 2025.
What are the primary conditions for the closing of this transaction?
The transaction is subject to customary closing conditions.
What is the filing date of this Form 8-K?
This Form 8-K was filed on May 13, 2025, reporting events as of May 9, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding INTEGRA LIFESCIENCES HOLDINGS CORP (IART).